Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 64.72
EXAS's Cash-to-Debt is ranked higher than
68% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. EXAS: 64.72 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.24  Med: No Debt Max: No Debt
Current: 64.72
Equity-to-Asset 0.89
EXAS's Equity-to-Asset is ranked higher than
93% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. EXAS: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.8 Max: 0.94
Current: 0.89
-0.41
0.94
Piotroski F-Score: 5
Altman Z-Score: 31.46
Beneish M-Score: -1.92
WACC vs ROIC
10.07%
-579.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -170.08
EXAS's Operating Margin % is ranked lower than
78% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. EXAS: -170.08 )
Ranked among companies with meaningful Operating Margin % only.
EXAS' s Operating Margin % Range Over the Past 10 Years
Min: -5591.71  Med: -420.54 Max: 1150.29
Current: -170.08
-5591.71
1150.29
Net Margin % -168.26
EXAS's Net Margin % is ranked lower than
78% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. EXAS: -168.26 )
Ranked among companies with meaningful Net Margin % only.
EXAS' s Net Margin % Range Over the Past 10 Years
Min: -5564.4  Med: -403.8 Max: 1123.53
Current: -168.26
-5564.4
1123.53
ROE % -53.52
EXAS's ROE % is ranked lower than
73% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. EXAS: -53.52 )
Ranked among companies with meaningful ROE % only.
EXAS' s ROE % Range Over the Past 10 Years
Min: -505.37  Med: -50.88 Max: -26.92
Current: -53.52
-505.37
-26.92
ROA % -47.60
EXAS's ROA % is ranked lower than
71% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. EXAS: -47.60 )
Ranked among companies with meaningful ROA % only.
EXAS' s ROA % Range Over the Past 10 Years
Min: -95.07  Med: -45.88 Max: -18.9
Current: -47.6
-95.07
-18.9
ROC (Joel Greenblatt) % -457.53
EXAS's ROC (Joel Greenblatt) % is ranked lower than
76% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. EXAS: -457.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3463.3  Med: -1718.22 Max: -457.53
Current: -457.53
-3463.3
-457.53
3-Year Revenue Growth Rate 151.60
EXAS's 3-Year Revenue Growth Rate is ranked higher than
97% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. EXAS: 151.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.2 Max: 302.1
Current: 151.6
0
302.1
3-Year EBITDA Growth Rate 31.60
EXAS's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. EXAS: 31.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.4  Med: -11.95 Max: 46.1
Current: 31.6
-39.4
46.1
3-Year EPS without NRI Growth Rate 33.20
EXAS's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. EXAS: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.1  Med: -14.35 Max: 46.5
Current: 33.2
-43.1
46.5
GuruFocus has detected 4 Warning Signs with Exact Sciences Corp $EXAS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EXAS Guru Trades in Q1 2016

Paul Tudor Jones 19,436 sh (New)
Jim Simons 210,100 sh (+1627.80%)
PRIMECAP Management 4,516,300 sh (+45.86%)
Steven Cohen 747,500 sh (-69.72%)
» More
Q2 2016

EXAS Guru Trades in Q2 2016

Joel Greenblatt 17,669 sh (New)
Columbia Wanger 770,000 sh (New)
PRIMECAP Management 4,516,300 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 507,175 sh (-32.15%)
» More
Q3 2016

EXAS Guru Trades in Q3 2016

Jim Simons 365,300 sh (New)
Paul Tudor Jones 32,756 sh (New)
Joel Greenblatt 53,252 sh (+201.39%)
Steven Cohen Sold Out
PRIMECAP Management 4,491,300 sh (-0.55%)
Columbia Wanger 558,434 sh (-27.48%)
» More
Q4 2016

EXAS Guru Trades in Q4 2016

Steven Cohen 153,000 sh (New)
Columbia Wanger 864,133 sh (+54.74%)
PRIMECAP Management 4,491,300 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:NAS:NEOG, NAS:MEDP, NAS:INCR, NAS:MYGN, NAS:KANG, NAS:AXDX, NAS:ABAX, NAS:ALOG, OTCPK:CZMWY, NAS:GHDX, NAS:PRXL, NAS:FMI, NYSE:ALR, NAS:VWR, NYSE:ARA, NAS:BEAT, NAS:QDEL, NAS:NEO, NAS:HSKA, NAS:PRAH » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non‑invasive, patient friendly screening test called Cologuard(R).

Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. It is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.

Ratios

vs
industry
vs
history
PB Ratio 6.54
EXAS's PB Ratio is ranked lower than
70% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. EXAS: 6.54 )
Ranked among companies with meaningful PB Ratio only.
EXAS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 6.61 Max: 36.44
Current: 6.54
1.69
36.44
PS Ratio 21.84
EXAS's PS Ratio is ranked lower than
87% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. EXAS: 21.84 )
Ranked among companies with meaningful PS Ratio only.
EXAS' s PS Ratio Range Over the Past 10 Years
Min: 9.28  Med: 44.87 Max: 1306.32
Current: 21.84
9.28
1306.32
EV-to-EBIT -11.93
EXAS's EV-to-EBIT is ranked lower than
99.99% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. EXAS: -11.93 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.7  Med: -10.3 Max: -0.3
Current: -11.93
-32.7
-0.3
EV-to-EBITDA -12.80
EXAS's EV-to-EBITDA is ranked lower than
99.99% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. EXAS: -12.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.4  Med: -10.7 Max: -0.4
Current: -12.8
-33.4
-0.4
Current Ratio 10.87
EXAS's Current Ratio is ranked higher than
95% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. EXAS: 10.87 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.95 Max: 20.02
Current: 10.87
1.02
20.02
Quick Ratio 10.65
EXAS's Quick Ratio is ranked higher than
95% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. EXAS: 10.65 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 9.95 Max: 20.02
Current: 10.65
1.02
20.02
Days Inventory 60.95
EXAS's Days Inventory is ranked higher than
57% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. EXAS: 60.95 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 54.55  Med: 79.66 Max: 169.5
Current: 60.95
54.55
169.5
Days Sales Outstanding 31.32
EXAS's Days Sales Outstanding is ranked higher than
85% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. EXAS: 31.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.32  Med: 45.66 Max: 279.33
Current: 31.32
31.32
279.33
Days Payable 5.73
EXAS's Days Payable is ranked lower than
84% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. EXAS: 5.73 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 5.73  Med: 1526.07 Max: 249295
Current: 5.73
5.73
249295

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
EXAS's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. EXAS: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -217.1  Med: -12.4 Max: -1
Current: -12.9
-217.1
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.14
EXAS's Price-to-Net-Cash is ranked higher than
61% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.06 vs. EXAS: 8.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EXAS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.8  Med: 6.29 Max: 36.14
Current: 8.14
2.8
36.14
Price-to-Net-Current-Asset-Value 7.52
EXAS's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. EXAS: 7.52 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.66  Med: 6.02 Max: 29.76
Current: 7.52
2.66
29.76
Price-to-Tangible-Book 6.53
EXAS's Price-to-Tangible-Book is ranked lower than
54% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. EXAS: 6.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.52  Med: 5.51 Max: 20.44
Current: 6.53
2.52
20.44
Price-to-Median-PS-Value 0.49
EXAS's Price-to-Median-PS-Value is ranked higher than
83% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. EXAS: 0.49 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 0.97 Max: 78.92
Current: 0.49
0.3
78.92
Earnings Yield (Greenblatt) % -8.42
EXAS's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. EXAS: -8.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -106.22  Med: 0 Max: 41.6
Current: -8.42
-106.22
41.6

More Statistics

Revenue (TTM) (Mil) $99.38
EPS (TTM) $ -1.64
Beta1.02
Short Percentage of Float33.80%
52-Week Range $4.67 - 23.68
Shares Outstanding (Mil)110.60

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 168 261 395
EPS ($) -1.47 -0.92 -0.23
EPS without NRI ($) -1.47 -0.92 -0.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Whitney Tilson's Robin Hood Conference Presentation Nov 19 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 

More From Other Websites
Pfizer's Leukemia Candidate Gets Priority Review in U.S. Feb 22 2017
Is EXAS Getting Ahead of Itself? Feb 22 2017
EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
[$$] Exact Sciences Is on Target for More Gains Feb 22 2017
EXACT Sciences upgraded by ROTH Capital Feb 22 2017
Edited Transcript of EXAS earnings conference call or presentation 21-Feb-17 3:00pm GMT Feb 21 2017
EXACT SCIENCES CORP Files SEC form 10-K, Annual Report Feb 21 2017
​Exact Sciences revenue jumps 152% as Cologuard use soars Feb 21 2017
Q4 2016 Exact Sciences Corp Earnings Release - Before Market Open Feb 21 2017
Exact Sciences reports 4Q loss Feb 21 2017
Exact Sciences reports 4Q loss Feb 21 2017
Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase Feb 21 2017
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS Feb 20 2017
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y Feb 16 2017
Key Presenters At Leerink's Healthcare Conference Feb 13 2017
The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis... Feb 08 2017
5 Great Biotech Stocks to Buy Now Feb 07 2017
CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)